This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mary Sano, PhD; D. P. Devanand, MD; Marcus Richards, PhD; Lisa W. Miller; Karen Marder, MD; Karen Bell, MD; George Dooneief, MD; Frederick W. Bylsma, PhD; Ginette Lafleche, PhD; Marilyn Albert, PhD; Marshal Folstein, MD; Yaakov Stern, PhD

Arch Neurol. 1995;52(10):961-966.

Abstract
Objectives
To develop an informant-based semistructured interview to determine the onset and duration of symptoms of Alzheimer's disease, and to use this instrument with informants to characterize a cohort of mildly impaired patients with Alzheimer's disease.

Design
In study 1, interrater and interinformant reliability was examined for the date of onset and the order of appearance for specific symptoms that were elicited by the semistructured onset interview. In study 2, the instrument was used to characterize disease onset in a cohort of patients with Alzheimer's disease who were participating in a large multicenter study.

Subjects
Informants of patients with Alzheimer's disease.

Results
In study 1, interrater reliability for duration of illness was excellent (intraclass correlation coefficient=.99, P<.001), and interinformant reliability was good (intraclass correlation coefficient=.86, P<.001). Agreement for the presence of a given symptom was highest for those that were most commonly reported (eg, memory and performance difficulty). In study 2, 89% of the cohort had memory problems, and 63.9% had performance difficulties as the first or second symptom. Depression and language problems were less commonly reported. Psychosis and behavioral disturbances were rarely reported as the first problem.

Conclusion
This instrument provides a reliable procedure for standardizing the estimation of duration of illness based on retrospective report.

Author Affiliations
From the Departments of Neurology (Drs Sano, Richards, Marder, Bell, Dooneief, and Stern and Ms Miller) and Psychiatry (Drs Devanand and Stern) and the Sergievsky Center (Drs Sano, Richards, and Stern), College of Physicians & Surgeons of Columbia University, the Memory Disorders Center, New York State Psychiatric Institute (Drs Sano, Devanand, Marder, Bell, Dooneief, and Stern and Ms Miller), and the Center for Alzheimer's Disease Research (Drs Sano, Marder, Bell, Dooneief, and Stern), New York, NY; the Departments of Psychiatry and Behavioral Sciences, The Johns Hopkins University, Baltimore, Md (Drs Bylsma and Folstein); and the Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (Drs Lafleche and Albert).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

VBM anticipates the rate of progression of Alzheimer disease: A 3-year longitudinal study
Kinkingnehun et al.
Neurology 2008;70:2201-2211.
ABSTRACT | FULL TEXT  

Cognitive Differences between Early- and Late-Onset Alzheimer's Disease
Licht et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2007;22:218-222.
ABSTRACT  

Long-term-care placement and survival of persons with Alzheimer's disease.
McClendon et al.
Journals of Gerontology Series B: Psychological Sciences and Social Science 2006;61:P220-P227.
ABSTRACT | FULL TEXT  

Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment
Devanand et al.
Arch Neurol 2005;62:975-980.
ABSTRACT | FULL TEXT  

Earlier Onset of Alzheimer Disease Symptoms in Latino Individuals Compared With Anglo Individuals
Clark et al.
Arch Neurol 2005;62:774-778.
ABSTRACT | FULL TEXT  

One-Year Change in Cerebral Glucose Metabolism in Patients With Alzheimer's Disease
Hirono et al.
J. Neuropsychiatry Clin. Neurosi. 2004;16:488-492.
ABSTRACT | FULL TEXT  

The effect of APOE {epsilon}4 allele on cerebral glucose metabolism in AD is a function of age at onset
Hirono et al.
Neurology 2002;58:743-750.
ABSTRACT | FULL TEXT  

Head circumference and incident Alzheimer's disease: Modification by apolipoprotein E
Borenstein Graves et al.
Neurology 2001;57:1453-1460.
ABSTRACT | FULL TEXT  

Impact of White Matter Changes on Clinical Manifestation of Alzheimer's Disease : A Quantitative Study
Hirono et al.
Stroke 2000;31:2182-2188.
ABSTRACT | FULL TEXT  

Effect of the Apolipoprotein E {epsilon}4 Allele on White Matter Hyperintensities in Dementia
Hirono et al.
Stroke 2000;31:1263-1268.
ABSTRACT | FULL TEXT  

Differences Between Pick Disease and Alzheimer Disease in Clinical Appearance and Rate of Cognitive Decline
Binetti et al.
Arch Neurol 2000;57:225-232.
ABSTRACT | FULL TEXT  

Distinctive Neurobehavioral Features Among Neurodegenerative Dementias
Hirono et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:498-503.
ABSTRACT | FULL TEXT  

Apolipoprotein E {epsilon}4 Allele and Whole Brain Atrophy in Late-Onset Alzheimer's Disease
Yasuda et al.
Am. J. Psychiatry 1998;155:779-784.
ABSTRACT | FULL TEXT  

Factors associated with psychotic symptoms in Alzheimer's disease
Hirono et al.
J. Neurol. Neurosurg. Psychiatry 1998;64:648-652.
ABSTRACT | FULL TEXT